Related Experiment Videos
Allogeneic immune replacement as cancer immunotherapy.
Sakti Chakrabarti1, Richard Childs
1National Heart, Lung, and Blood Institute, Hematology branch, 9000 Rockville Pike, Bethesda, Maryland 20892, USA.
Expert Opinion on Biological Therapy
|October 2, 2003
Summary
Allogeneic cell transplantation harnesses the donor immune system to combat cancers. This approach shows promise as a powerful immunotherapy for both blood cancers and solid tumors.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- Allogeneic haematopoietic cell transplantation (HCT) utilizes the graft-versus-leukaemia (GVL) reaction to treat haematological malignancies.
- Reduced intensity transplant approaches leverage the donor immune system for antitumour effects.
- The GVL effect's success has prompted investigations into graft-versus-tumour (GVT) effects in solid tumours.
Purpose of the Study:
- To review the evidence supporting immune replacement after allogeneic HCT as a cancer immunotherapy.
- To explore the efficacy of GVT effects in treatment-refractory metastatic solid tumours.
- To highlight the potential of allogeneic HCT in treating both haematological and non-haematological malignancies.
Main Methods:
- Literature review of studies on allogeneic HCT and its antitumour effects.
- Analysis of clinical trial data for graft-versus-tumour responses.
- Synthesis of evidence on immune replacement as a therapeutic strategy.
Main Results:
- Allogeneic HCT demonstrates significant antitumour effects through GVL and GVT reactions.
- Reduced intensity HCT enables donor immune system-mediated cancer eradication.
- Promising GVT effects are observed in patients with metastatic solid tumours.
Conclusions:
- Immune replacement following allogeneic HCT is a potent immunotherapy for diverse cancers.
- Allogeneic HCT offers a viable treatment option for refractory leukaemias and solid tumours.
- Further research into GVT effects can expand HCT applications in oncology.